DDInter1570 DDInter448
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Ranolazine {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Organic Cation Transporter 2 Inhibitors
Organic Cation Transporter 2 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Crizotinib
Ranolazine {u} (Compound) downregulates {v} (Gene) SDHB
SDHB {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Ranolazine {u} (Compound) causes {v} (Side Effect) Dizziness postural
Dizziness postural {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Ranolazine {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) is regulated by {v} (Gene) IGF1R
IGF1R {u} (Gene) is bound by {v} (Compound) Crizotinib
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Organic Cation Transporter 2 Inhibitors
Organic Cation Transporter 2 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Dolutegravir
Dolutegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Cytochrome P450 3A Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ivacaftor
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Ranolazine (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is upregulated by Crizotinib (Compound)
Ranolazine (Compound) is included by Organic Cation Transporter 2 Inhibitors (Pharmacologic Class) and Organic Cation Transporter 2 Inhibitors (Pharmacologic Class) includes Crizotinib (Compound)
Ranolazine (Compound) downregulates SDHB (Gene) and SDHB (Gene) is downregulated by Crizotinib (Compound)
Ranolazine (Compound) causes Dizziness postural (Side Effect) and Dizziness postural (Side Effect) is caused by Crizotinib (Compound)
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Ranolazine (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) is regulated by IGF1R (Gene) and IGF1R (Gene) is bound by Crizotinib (Compound)
Ranolazine (Compound) is included by Organic Cation Transporter 2 Inhibitors (Pharmacologic Class) and Organic Cation Transporter 2 Inhibitors (Pharmacologic Class) includes Dolutegravir (Compound) and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Ranolazine (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class) and Cytochrome P450 3A Inhibitors (Pharmacologic Class) includes Ivacaftor (Compound) and Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib